Traders should anticipate downward pressure on RCUS shares due to the failure of a pivotal Phase 3 trial and reduced strategic partnership optionality with Gilead. Monitor upcoming presentations for detailed data from the futility analysis and assess implications for other TIGIT-targeting therapies in development.
RCUS drugs
RCUS drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 20 $22.74entry
- T+1 · 7mo ago +7.83%α +8.48% · $24.52
- T+5 · 7mo ago +9.72%α +8.81% · $24.95
- T+20 · 6mo ago +2.90%α −1.30% · $23.40
- T+60 · 4mo ago +23.22%α +16.44% · $28.02
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Arcus Biosciences announced the discontinuation of its Phase 3 STAR-121 trial in metastatic non-small cell lung cancer due to futility, based on an independent data monitoring committee's recommendation. Additionally, Gilead will not extend its option rights to Arcus's early-stage pipeline programs beyond July 14, 2026, retaining only limited existing options.
Key Facts
- Phase 3 STAR-121 study evaluating domvanalimab + zimberelimab + chemo vs. pembrolizumab + chemo in first-line metastatic NSCLC discontinued due to futility
- Decision based on pre-planned futility analysis by Independent Data Monitoring Committee (IDMC); safety not assessed at this stage
- Exploratory endpoint showed zimberelimab + chemo performed consistently with pembrolizumab + chemo on overall survival
- Phase 2 EDGE-Lung study also being discontinued
- Gilead will not make option continuation payment, ending its rights to early-stage programs (CCR6, CD89, CD40L) after July 14, 2026
- Gilead retains time-limited options to AB801, AB598, AB102, and an investigational TNF inhibitor
- Arcus regains full rights to casdatifan development program outside of Taiho-licensed territories
Financial Impact
Significant negative impact expected due to loss of late-stage oncology program and reduced partnership value with Gilead; no specific financial figures disclosed
Risk Factors
- Further devaluation of Arcus's immuno-oncology pipeline
- Reduced likelihood of near-term partnership or acquisition interest
- Potential for additional trial discontinuations in related programs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001724521-26-000021 |
| Document: 0001724521-26-000021-index.html | 0001724521-26-000021 |
| Document: 0001724521-26-000021.txt | 0001724521-26-000021 |
Track record
13 reports on RCUS
2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +4.24% at T+1 after the Oct 21, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 16, 2026today Institutional Cluster Neutral 3/10 Entry $16.95 Now $16.86 −0.53% settles Nov 23
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $18.95 to $16.86 Now $16.86 −11.03% ▼ −11.03% −9.34% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $17.69 to $17.77 Now $16.86 −4.69% ▲ +0.45% −2.84% vs SPY
- Oct 23, 202624d ago 8-K Bearish 5/10 Entry $17.76 to $18.19 Now $16.86 +5.07% ▼ −2.42% −3.68% vs SPY
- Oct 22, 202625d ago 424B5 Bearish 6/10 Entry $18.54 to $18.19 Now $16.86 +9.06% ▲ +1.89% +1.33% vs SPY
- Oct 21, 202626d ago 424B5 Bearish 5/10 Entry $19.36 to $18.61 Now $16.86 +12.91% ▲ +3.87% +4.58% vs SPY
- Oct 21, 202626d ago 8-K Neutral 4/10 Entry $19.36 to $18.61 Now $16.86 −12.91% ▼ −3.87% −4.58% vs SPY
- Oct 20, 202627d ago 8-K Neutral 4/10 Entry $23.75 to $18.14 Now $16.86 −29.01% ▼ −23.62% −23.70% vs SPY
- Jul 9, 202618w ago 144 Neutral 3/10 Entry $28.92 to $26.64 Now $16.86 −41.70% ▼ −7.88% −7.32% vs SPY
- Apr 21, 202629w ago DEFA14A Neutral 2/10 Entry $26.62 to $24.55 Now $16.86 −36.66% ▼ −7.79% −7.85% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers